Spots Global Cancer Trial Database for stage iii colon cancer ajcc v8

Every month we try and update this database with for stage iii colon cancer ajcc v8 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer	NCT03992456	Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... Unresectable Co... Unresectable Co... Unresectable Re...	Panitumumab Quality-of-Life... Questionnaire A... Regorafenib Trifluridine an...	18 Years -	Academic and Community Cancer Research United
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial	NCT03765736	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta... Unresectable Co... Unresectable Re...	Genetic Testing	18 Years -	Academic and Community Cancer Research United
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	NCT04362839	Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta...	Ipilimumab Nivolumab Regorafenib	18 Years -	City of Hope Medical Center
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial	NCT04704661	Advanced Breast... Advanced Colon ... Advanced Colore... Advanced Endome... Advanced Gastri... Advanced Gastro... Advanced Malign... Advanced Saliva... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... HER2-Positive B... Malignant Hepat... Metastatic Brea... Metastatic Gast... Metastatic Mali... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Pathologic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Stage III Colon... Stage III Color... Stage III Major... Stage III Uteri... Stage IIIA Colo... Stage IIIA Colo... Stage IIIA Uter... Stage IIIB Colo... Stage IIIB Colo... Stage IIIB Uter... Stage IIIC Colo... Stage IIIC Colo... Stage IIIC Uter... Stage IIIC1 Ute... Stage IIIC2 Ute... Stage IV Colon ... Stage IV Colore... Stage IV Major ... Stage IV Uterin... Stage IVA Colon... Stage IVA Color... Stage IVA Major... Stage IVA Uteri... Stage IVB Colon... Stage IVB Color... Stage IVB Major... Stage IVB Uteri... Stage IVC Colon... Stage IVC Color... Stage IVC Major... Unresectable Co... Unresectable Ga... Unresectable Ma...	Ceralasertib Trastuzumab Der...	18 Years -	National Cancer Institute (NCI)
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer	NCT05710406	Colon Adenocarc... Microsatellite ... Stage IIB Colon... Stage IIC Colon... Stage III Colon...	Encorafenib Cetuximab Biospecimen Col... Computed Tomogr... Magnetic Resona... Patient Observa...	18 Years -	Alliance for Clinical Trials in Oncology
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	NCT05308446	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	National Cancer Institute (NCI)
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	NCT04362839	Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta...	Ipilimumab Nivolumab Regorafenib	18 Years -	City of Hope Medical Center
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer	NCT05710406	Colon Adenocarc... Microsatellite ... Stage IIB Colon... Stage IIC Colon... Stage III Colon...	Encorafenib Cetuximab Biospecimen Col... Computed Tomogr... Magnetic Resona... Patient Observa...	18 Years -	Alliance for Clinical Trials in Oncology
Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment	NCT03516942	Stage I Colon C... Stage I Rectal ... Stage II Colon ... Stage II Rectal... Stage IIA Colon... Stage IIA Recta... Stage IIB Colon... Stage IIB Recta... Stage IIC Colon... Stage IIC Recta... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect...	Quality-of-Life... Questionnaire A...	18 Years -	Eastern Cooperative Oncology Group
Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair	NCT02912559	Colon Adenocarc... DNA Repair Diso... Lynch Syndrome Stage III Colon...	Atezolizumab Biospecimen Col... Computed Tomogr... Fluorouracil Leucovorin Calc... Magnetic Resona... Oxaliplatin Quality-of-Life...	12 Years -	National Cancer Institute (NCI)
Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial	NCT03765736	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta... Unresectable Co... Unresectable Re...	Genetic Testing	18 Years -	Academic and Community Cancer Research United
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study	NCT04109924	Advanced Colore... Metastatic Colo... Metastatic Rect... Recurrent Colon... Recurrent Color... Recurrent Recta... Stage III Colon... Stage III Color... Stage III Recta... Stage IIIA Colo... Stage IIIA Colo... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Colo... Stage IV Colon ... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta... Unresectable Co... Unresectable Co... Unresectable Re...	Irinotecan Bevacizumab Trifluridine an...	18 Years -	Roswell Park Cancer Institute
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation	NCT05308446	Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IV Colon ... Stage IV Rectal... Unresectable Co... Unresectable Re...	Cetuximab Encorafenib Nivolumab	18 Years -	National Cancer Institute (NCI)
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer	NCT04362839	Advanced Colon ... Metastatic Colo... Metastatic Colo... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Colore... Stage IV Rectal... Stage IVA Colon... Stage IVA Color... Stage IVA Recta... Stage IVB Colon... Stage IVB Color... Stage IVB Recta... Stage IVC Colon... Stage IVC Color... Stage IVC Recta...	Ipilimumab Nivolumab Regorafenib	18 Years -	City of Hope Medical Center
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer	NCT03592641	Colorectal Carc... Metastatic Colo... Metastatic Rect... Stage III Colon... Stage III Recta... Stage IIIA Colo... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Rect... Stage IV Colon ... Stage IV Rectal... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta... Stage IVC Colon... Stage IVC Recta... Unresectable Co... Unresectable Re...	Savolitinib	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: